Karen Lin
Research Subjects
Karen Lin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alan Tan
Vanderbilt University Medical Center, Nashville, TN
16 shared publications - Andrew Stewart Poklepovic
Virginia Commonwealth University Health System, Richmond, VA
16 shared publications - Bently Patrick Doonan
University of Florida 5 , Gainesville, Florida
16 shared publications - Daniel B. Flora
10St Elizabeth Cancer Center, Edgewood, Kentucky
16 shared publications - Elise K. Brunsgaard
30Department of Surgery, University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, Utah
16 shared publications - George Ansstas
Washington University School of Medicine, St. Louis, MO, USA
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Distribution of lead time between ctDNA detection and imaging-confirmed recurrence using the first ctDNA-positive sample prior to recurrence. Each dot represents an individual patient with green dots representing patients who became ctDNA-positive and whose initial post-positivity imaging remained negative with recurrence confirmed on subsequent imaging.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
A, Kaplan–Meier RFS curves stratified by ctDNA status among patients who received adjuvant systemic therapy. Anytime ctDNA positivity was associated with significantly inferior RFS. B, Kaplan–Meier RFS curves stratified by ctDNA status among patients who did not receive adjuvant therapy, showing a similar strong association between ctDNA positivity and recurrence. C, Sankey diagram illustrating ctDNA dynamics after systemic therapy initiation among 53 patients with ≥1 on-treatment ctDNA timepoint. Of the 8 patients who recurred, 2 exhibited persistent ctDNA positivity or converted from ctDNA-negative to ctDNA-positive despite treatment. A subset demonstrated transient clearance before recurrence.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Representativeness of the study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIB melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIA melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IA/B melanoma.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIC melanoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Overview plot of patients with stage IIC melanoma.